Dan Skovronsky

New Capabilities

Leading Lilly's research programs including obesity drug development

Adults with obesity and type 2 diabetes who took Eli Lilly's experimental EloraTZP lost an average of 23.3% of their body weight over 48 weeks — well beyond the 14.8% lost by those on tirzepatide alone, the drug sold as Zepbound. The combination pairs tirzepatide, a dual GIP and GLP-1 receptor agonist, with eloralintide, a selective amylin receptor agonist, engaging three appetite-regulating hormone pathways at once.

Updated Oct 18